Analysts Offer Insights on Healthcare Companies: Cerecor Inc (CERC), uniQure NV (QURE) and Alkermes (ALKS)


Analysts have been eager to weigh in on the Healthcare sector with new ratings on Cerecor Inc (CERC), uniQure NV (QURE) and Alkermes (ALKS).

Cerecor Inc (CERC)

In a report released today, Ram Selvaraju from H.C. Wainwright reiterated a Buy rating on Cerecor Inc, with a price target of $11. The company’s shares closed yesterday at $4.25.

Selvaraju said:

“We value Cerecor based on a discounted cash flow (DCF) approach that yields a total value of $530M, or a price objective of $11.00 per share, based on our projection of 47.3M shares outstanding as of end-1Q 2020. We utilize a 13% discount rate, along with an effective tax rate of 29.7%.”

According to TipRanks.com, Selvaraju ‘s ranking currently consits of no stars on a 0-5 ranking scale, with an average return of -6.2% and a 30.1% success rate. Selvaraju covers the Healthcare sector, focusing on stocks such as Taro Pharmaceutical Industries Ltd., Biospecifics Technologies Corp, and EyePoint Pharmaceuticals Inc.

The word on The Street in general, suggests a Strong Buy analyst consensus rating for Cerecor Inc with a $9.67 average price target.

See today’s analyst top recommended stocks >>

uniQure NV (QURE)

H.C. Wainwright analyst Debjit Chattopadhyay maintained a Buy rating on uniQure NV today and set a price target of $73. The company’s shares closed yesterday at $62.03.

Chattopadhyay wrote:

“Our $73 target is based on a 12-year DCF analysis that incorporates rNPV of two clinical-stage pipeline products AMT-061 and AMT-130. For AMT-061, we assume a 70% POS driven by the compelling clinical updates and single-arm Phase 3 involving about 50 patients, along with RMAT and PRIME designations. We anticipate commercial launch during 2H22, with a NAB-based exclusion of 5%, and model risk-adjusted peak sales of roughly $900M, during 2028. We assume a launch price of $1M, which could be a low estimate based on the seven-plus years of anticipated durability.”

According to TipRanks.com, Chattopadhyay is a 2-star analyst with an average return of 0.0% and a 46.6% success rate. Chattopadhyay covers the Healthcare sector, focusing on stocks such as Global Blood Therapeutics, Precision BioSciences Inc, and Voyager Therapeutics Inc.

Currently, the analyst consensus on uniQure NV is a Strong Buy with an average price target of $99.60.

Alkermes (ALKS)

H.C. Wainwright analyst Douglas Tsao maintained a Hold rating on Alkermes today and set a price target of $28. The company’s shares closed yesterday at $21.86, close to its 52-week low of $19.85.

Tsao wrote:

“Our $28 price target for Alkermes is based on our sum- of-the-parts NPV valuation based on each of the company’s marketed products and pipeline assets. Our DCF model utilizes a discount rate of 13.1% based on the company’s WACC (Beta of 1.9, equity risk premium of 6.7%).”

According to TipRanks.com, Tsao is a 1-star analyst with an average return of -0.3% and a 47.0% success rate. Tsao covers the Healthcare sector, focusing on stocks such as Crinetics Pharmaceuticals Inc, Outlook Therapeutics Inc, and Protagonist Therapeutics.

The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Alkermes with a $28.29 average price target, a 29.4% upside from current levels. In a report issued on July 15, Goldman Sachs also upgraded the stock to Hold with a $27 price target.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Stay Ahead of Everyone Else

Get The Latest Stock News Alerts